Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03455725 · ClinicalTrials.gov registry record · NA
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
A NA study of Refractory Angina and Chronic Myocardial Ischemia, sponsored by BioCardia.
- Active
- Registry status
- NA
- Development phase
- 343
- Enrollment target
- 2
- Study locations
NCT03455725: Active NA study of Refractory Angina and Chronic Myocardial Ischemia, sponsored by BioCardia.
NCT03455725 is a NA study of Refractory Angina and Chronic Myocardial Ischemia that is active but no longer recruiting, run by BioCardia. The registered enrollment target is 343 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03455725, a NA study of Refractory Angina and Chronic Myocardial Ischemia, is active but no longer recruiting, sponsored by BioCardia.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 343 participants
- Enrollment target
- 2
- Study locations
Study Summary
Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)
Primary Outcome
A superiority analysis with regards to change from Baseline in Total Exercise Time at the 6 months follow-up visit (using a Modified Bruce Protocol).
Conditions Studied
Interventions
- DEVICE CardiAMP Cell Therapy System
- OTHER Sham Treatment
Study Locations (2)
Florida
- University of Florida - Gainesville
Wisconsin
- University of Wisconsin Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT03455725 still lists
NCT03455725 is an interventional study that assigns participants to a tested intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Refractory Angina appearing as the primary indexed condition, and to 2 interventions - of which CardiAMP Cell Therapy System is the first listed.
NCT03455725 reports a single indexed study location in Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03455725 about?
NCT03455725 is a clinical study titled "CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial". Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subject...
What is the current status of trial NCT03455725?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 343 participants. The study started on 2021-06-30. Estimated completion is 2027-12.
What conditions does trial NCT03455725 study?
This clinical trial studies the following conditions: Refractory Angina, Chronic Myocardial Ischemia.
What interventions are being tested in trial NCT03455725?
The interventions under investigation include: CardiAMP Cell Therapy System (DEVICE), Sham Treatment (OTHER).
Who is sponsoring clinical trial NCT03455725?
This trial is sponsored by BioCardia, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03455725 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Angina
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03455725's enrollment target sits among peer trials
343 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI